Sermorelin
The shortest fully active fragment of human growth-hormone-releasing hormone, a benchmark compound in GH-axis pharmacology.
$119.00 USD / vial
Vial size
Research use only. This material is supplied exclusively for lawful in-vitro laboratory research, analytical testing, and scientific study by qualified professionals. Not for human or veterinary use of any kind.
About Sermorelin
Sermorelin corresponds to the first 29 amino acids of human growth-hormone-releasing hormone (GHRH 1-29), the minimal fragment shown to retain full receptor-binding activity at the GHRH receptor. Its well-characterized structure has made it a reference point against which longer-acting analogs, including stabilized variants such as Tesamorelin, are routinely compared.
Because it acts upstream at the GHRH receptor rather than the ghrelin/GHS receptor, it is frequently paired with secretagogues like Ipamorelin in comparative GH-axis research. Supplied lyophilized with independent lot verification.
Documented research areas
- GHRH receptor-binding and signaling studies
- Comparative GH-axis secretagogue research
- Pulsatile GH-release modeling
- Peptide fragment structure–activity studies
Technical profile
| CAS Number | 86168-78-7 |
|---|---|
| Molecular Formula | C149H246N44O42S |
| Molecular Weight | 3357.9 g/mol |
| Class | GHRH (1-29) fragment |
| Form | Lyophilized powder |
| Purity | ≥ 99% (HPLC) |
| Storage | −20 °C, protect from light |
Testing & documentation
Every production lot of Sermorelin is analyzed by an independent third-party laboratory before release. Identity is confirmed by mass spectrometry and purity is quantified by high-performance liquid chromatography (HPLC), with a minimum release threshold of 99%.
A lot-specific Certificate of Analysis is available on request, email support@elevatebiolabs.co. Vials are filled and sealed under laboratory-standard conditions and shipped in tamper-evident packaging.